Trifecta of clinical stage biotechs unveil IPO plans, braving Wall Street's coronavirus panic
Coronavirus fears precipitated a rout on global stock prices on Monday, but three clinical-stage biotechs are soldiering on with plans to make public debuts. The biggest is Zentalis Pharmaceuticals — which is gunning for a $100 million IPO, three months after an $85 million round of financing.
Founded in late 2014, the oncology company emerged out of stealth in late 2019 with the Series C round. So far the company has raised about $162 million in gross proceeds.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.